Worldwide first for electrical cold sore treatment
This article was originally published in Clinica
Executive Summary
NexMed is poised to enter the $3.7 billion herpes market monopolised by pharmaceutical companies following Canadian approval to market its Viratrol system for treating oral herpes, or cold sores. This is the first approval worldwide for the hand-held, non-invasive device which will be in direct competition with Glaxo Wellcome's acyclovir drug treatment.